The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics
Open accessAbstract
Since the unexpected discovery of the antipsychotic activity of chlorpromazine, a variety of therapeutic agents have been developed for the treatment of schizophrenia. Despite differences in their activities at various neurotransmitter systems, all clinically effective antipsychotics share the ability to interact with D2 class dopamine receptors (D2R). D2R mediate their physiological effects via both G protein-dependent and independent (β-arrestin 2-dependent) signaling, but the role of these D2R-mediated signaling events in the actions of antipsychotics remains unclear. We demonstrate here that while different classes of antipsychotics have complex pharmacological profiles at G protein-dependent D2R long isoform (D2 L R) signaling, they share the common property of antagonizing dopamine-mediated interaction of D2 L R with β-arrestin 2. Using two cellular assays based on a bioluminescence resonance energy transfer (BRET) approach, we demonstrate that a series of antipsychotics including haloperidol, clozapine, aripiprazole, chlorpromazine, quetiapine, olanzapine, risperidone, and ziprasidone all potently antagonize the β-arrestin 2 recruitment to D2 L R induced by quinpirole. However, these antipsychotics have various effects on D2 L R mediated G i/o protein activation ranging from inverse to partial agonists and antagonists with highly variable efficacies and potencies at quinpirole-induced cAMP inhibition. These results suggest that the different classes of clinically effective antipsychotics share a common molecular mechanism involving inhibition of D2 L R/β-arrestin 2 mediated signaling. Thus, selective targeting of D2 L R/β-arrestin 2 interaction and related signaling pathways may provide new opportunities for antipsychotic development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 1×
“Generally, these compounds can be divided in 3 different categories: conventional (typical) antipsychotics, atypical antipsychotics, and the recentlyintroduced dopamine receptor partial agonist antipsychotics (dopamine-serotonin system stabilizers) (1).”
BackgroundDistinct functions of the two isoforms of dopamine D2 receptors
Usiello, A., Baik, J.-H., Rougé-Pont, F., Picetti, R., Dierich, A., LeMeur, M., Piazza, P. V., & Borrelli, E. (2000) · Nature · doi:10.1038/35041572 · Cited by 717
Prickaerts, J., Moechars, D., Cryns, K., Lenaerts, I., van Craenendonck, H., Goris, I., Daneels, G., Bouwknecht, J. A., & Steckler, T. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5216-05.2006 · Cited by 341
Hamdan, F. F., Audet, M., Garneau, P., Pelletier, J., & Bouvier, M. (2005) · SLAS Discovery · doi:10.1177/1087057105275344 · Cited by 183
Cited by
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Self-citationRemote Control of Neuronal Signaling
Rogan, S. C., & Roth, B. L. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003020 · Cited by 339
The role of kinetic context in apparent biased agonism at GPCRs
Klein Herenbrink, C., Sykes, D. A., Donthamsetti, P., Canals, M., Coudrat, T., Shonberg, J., Scammells, P. J., Capuano, B., Sexton, P. M., Charlton, S. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10842 · Cited by 328
Strategies to Discover Unexpected Targets for Drugs Active at G Protein–Coupled Receptors
Allen, J. A., & Roth, B. L. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100553 · Cited by 216
Law, A. J., Wang, Y., Sei, Y., O’Donnell, P., Piantadosi, P., Papaleo, F., Straub, R. E., Huang, W., Thomas, C. J., Vakkalanka, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206118109 · Cited by 147
Labeling and Single-Molecule Methods To Monitor G Protein-Coupled Receptor Dynamics
Tian, H., Fürstenberg, A., & Huber, T. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00084 · Cited by 114
Trace Amine-Associated Receptors as Emerging Therapeutic Targets
Sotnikova, T. D., Caron, M. G., & Gainetdinov, R. R. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.055970 · Cited by 97
Self-citationElucidation of G-protein and β-arrestin functional selectivity at the dopamine D2 receptor
Peterson, S. M., Pack, T. F., Wilkins, A. D., Urs, N. M., Urban, D. J., Bass, C. E., Lichtarge, O., & Caron, M. G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502742112 · Cited by 91
Self-citationJeremic, D., Sanchez-Rodriguez, I., Jimenez-Diaz, L., & Navarro-Lopez, J. D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107808 · Cited by 89
Föcking, M., Dicker, P., English, J. A., Schubert, K. O., Dunn, M. J., & Cotter, D. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.43 · Cited by 90
de Bartolomeis, A., Buonaguro, E. F., & Iasevoli, F. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2921-8 · Cited by 89
Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review
Yuen, J. W. Y., Kim, D. D., Procyshyn, R. M., White, R. F., Honer, W. G., & Barr, A. M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00203 · Cited by 79
Intervention in the Context of Development: Pathways Toward New Treatments
Veenstra-VanderWeele, J., & Warren, Z. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.232 · Cited by 34
Metadata
- Authors
- Masri, B., Salahpour, A., Didriksen, M., Ghisi, V., Beaulieu, J.-M., Gainetdinov, R. R., & Caron, M. G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-09-09
- Volume
- 105
- Issue
- 36
- Pages
- 13656-13661
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2126132542
- Cited by
- 320
- References
- 6
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
